PF-02341066 |
XALKORI |
CRIZOTINIB |
PF-2341066 |
XALKORI® |
PF2341066 |
(R)-CRIZOTINIB |
PF 2341066 |
chembl:CHEMBL601719 |
rxcui:1148495 |
drugbank:08700 |
chemidplus:877399-52-5 |
pubchem.compound:11626560 |
Pharmaceutical Developer | Pfizer |
Source Reported Drug Name(s) | Crizotinib/Xalkori/PF-02341066 |
Drug Class | ALK Inhibitor |
FDA Approval | approved |
Drug Class | Small molecule |
Drug Indications | antineoplastic agent |
FDA Approval | Non-small cell lung cancer (with ALK fusion or ROS1 gene alteration) |
Drug Class | Kinase Inhibitors |
Drug Categories | amines |
Drug Categories | aminopyridines |
Drug Categories | cytochrome p-450 cyp2b6 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors |
Drug Categories | cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 cyp3a5 inhibitors |
Drug Categories | cytochrome p-450 cyp3a5 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a5 substrates |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | kinase inhibitor |
Drug Categories | oct2 inhibitors |
Drug Categories | organic cation transporter 1 inhibitors |
Drug Categories | p-glycoprotein inhibitors |
Drug Categories | p-glycoprotein substrates |
Drug Categories | p-glycoprotein substrates with narrow therapeutic index |
Drug Categories | piperidines |
Drug Categories | pyridines |
Drug Categories | qtc prolonging agents |
Drug Categories | receptor tyrosine kinase inhibitors |
Drug Categories | tyrosine kinase inhibitors |
n/a |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | sensitive |
Approval Status | Preclinical |
inhibitor (inhibitory) |
Alteration | ALK:C1156Y,L1196M |
Alteration | ALK:L1198F |
Alteration | ALK:F856S,A348D |
inhibitor (inhibitory) |
Clinical Status | case report |
Pathway | activation |
Variant Effect | gain-of-function |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
n/a |
Drug family | ALK inhibitor |
Alteration | ABL1:V299L |
n/a |
Indication/Tumor Type | lung cancer |
Response Type | resistant |
Approval Status | Preclinical |
n/a |
combination therapy | Crizotinib;Vemurafenib |
Drug family | ALK inhibitor;BRAF inhibitor |
Alteration | MET:amp;BRAF:V600E |
CRIZOTINIB | DrugBank Drug Name |
877399-52-5 | CAS Number |
Xalkori | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Categories | amines |
Crizotinib | PubChem Drug Name |
11626560 | PubChem Drug ID |
Xalkori | Drug Trade Name |
Drug Class | ALK Inhibitor |
Source Reported Drug Name(s) | Crizotinib/Xalkori/PF-02341066 |
Pharmaceutical Developer | Pfizer |
PF-02341066 | Development Name |
CRIZOTINIB | Generic Name |
XALKORI | Trade Name |
Drug Class | Kinase Inhibitors |
FDA Approval | Non-small cell lung cancer (with ALK fusion or ROS1 gene alteration) |
Drug Indications | antineoplastic agent |
Drug Class | Small molecule |
FDA Approval | approved |
CHEMBL601719 | ChEMBL Drug ID |
CRIZOTINIB | Primary Drug Name |
CRIZOTINIB | Drug Generic Name |
XALKORI | Drug Trade Name |
D03ZBT | TTD Drug ID |
CRIZOTINIB | GuideToPharmacology Ligand Name |